Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Long-Term Investments (2022 - 2025)

Tarsus Pharmaceuticals (TARS) has 4 years of Long-Term Investments data on record, last reported at $3.9 million in Q4 2025.

  • For Q4 2025, Long-Term Investments rose 29.0% year-over-year to $3.9 million; the TTM value through Dec 2025 reached $3.9 million, up 29.0%, while the annual FY2025 figure was $3.9 million, 29.0% up from the prior year.
  • Long-Term Investments reached $3.9 million in Q4 2025 per TARS's latest filing, up from $3.0 million in the prior quarter.
  • Across five years, Long-Term Investments topped out at $3.9 million in Q4 2025 and bottomed at $157000.0 in Q3 2022.
  • Average Long-Term Investments over 4 years is $1.7 million, with a median of $1.8 million recorded in 2023.
  • Peak YoY movement for Long-Term Investments: soared 1328.57% in 2024, then changed 0.0% in 2025.
  • A 4-year view of Long-Term Investments shows it stood at $371000.0 in 2022, then soared by 70.08% to $631000.0 in 2023, then surged by 375.44% to $3.0 million in 2024, then increased by 29.0% to $3.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Long-Term Investments were $3.9 million in Q4 2025, $3.0 million in Q3 2025, and $3.0 million in Q2 2025.